

Effect of Gender on the Progression of Nondiabetic Renal Disease: A Meta-Analysis

JOEL NEUGARTEN, ANJALI ACHARYA, and SHARON R. SILBIGER

Renal Division, Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.

Abstract. There is previously published evidence that male gender is associated with a more rapid rate of progression of nondiabetic chronic renal disease. However, some investigators have concluded that no such association exists. To help resolve this issue, a meta-analysis was performed using 68

studies that met defined criteria and contained a total of 11,345 patients to evaluate the effect of gender on the progression of nondiabetic chronic renal disease. The results indicate that men with chronic renal disease of various etiologies show a more rapid decline in renal function with time than do women.

We have previously provided evidence that male gender is associated with a more rapid rate of progression of nondiabetic chronic renal disease (1). However, other investigators have concluded that no such association exists (2). Moreover, the results of individual studies have not universally found an adverse effect of male gender on the progression of renal disease (1). To help resolve this issue, we performed a meta-analysis using 68 studies that met defined criteria and contained a total of 11,345 patients to evaluate the effect of gender on the progression of nondiabetic chronic renal disease. The results indicate that men with chronic renal disease of various etiologies show a more rapid decline in renal function with time than do women.

Materials and Methods

Published reports examining the effect of gender on the progression of nondiabetic chronic renal disease (CRD) (mixed etiology), IgA nephropathy, idiopathic membranous nephropathy, and autosomal dominant polycystic kidney disease (ADPKD) were identified by conducting a search of articles indexed in the Medline database for the years 1975–1998. The search was conducted by: (1) cross-referencing the terms “glomerulonephritis,” “nephritis,” and “nephropathy” with “IgA,” “Berger’s,” and “membranous;” (2) cross-referencing the term “gender” and the key words “sex factors” with the terms “renal” and “kidney;” and (3) using the key words “kidney disease” and “polycystic.” Additional studies were identified through examination of the bibliography of retrieved articles. From this group, we identified those studies that specifically examined the impact of gender on renal disease progression in humans. Selection was limited to studies with 25 or more subjects followed for an average of 6 mo or longer. Unpublished abstracts and letters to the editor were not included

unless they updated a previously published study. Studies written in a language other than English were not included unless identified through a bibliographic citation. Multiple publications from the same investigators were carefully examined to exclude duplication of subjects. Two investigators independently examined each retrieved study and extracted the following data: year of publication, number of male and female subjects, study design, administered treatment, statistical analysis, and outcome measure.

Meta-analyses were performed on all identified studies within each of the study categories (CRD, IgA nephropathy, membranous nephropathy, ADPKD) using a fixed-effects model. Meta-analyses were repeated after excluding those studies that failed to use one of the following outcome measures: end-stage renal disease (ESRD) requiring renal replacement therapy, change in isotopically determined GFR, or, in the case of ADPKD only, age of institution of renal replacement therapy.

Meta-analyses were conducted according to the method of Hedges and Olkin (3). Calculations were made using DSTAT 1.10 with a fixed-effects model (4). The standardized effect size estimate (d value) was calculated for each study as the difference between outcomes of men and women expressed as SD units. A mean effect size and a 95% confidence interval (CI) were calculated by averaging all d values weighted by the reciprocal of their variance. The mean weighted correlation, r , was also calculated. The Q statistic was calculated as a measure of heterogeneity of effect size.

Meta-analyses were repeated using the random-effects model of DerSimonian and Laird (5). The standardized effect size estimate and Q statistic were calculated as described (5).

A meta-regression analysis was performed to delineate possible reasons for heterogeneity among the studies. Standardized effect size estimate was the dependent variable, and the following were independent variables: year of publication, total number of subjects, number of male subjects, number of female subjects, mean patient age, year of study publication, immunosuppressive therapy, minimum duration of follow-up, mean duration of follow-up, outcome measure, type of renal disease, and study quality (retrospective, prospective observational, randomized-controlled, etc).

A funnel plot was constructed of standardized effect size *versus* subject number to assess publication bias. Unequal distribution of points above and below the mean standardized effect size suggests publication bias (6).

Received May 24, 1999. Accepted July 31, 1999.

Correspondence to Dr. Joel Neugarten, Renal Laboratory, Montefiore Medical Center, 111 East 210 Street, Bronx, NY 10467. Phone: 718-920-4991; Fax: 718-920-6658.

1046-6673/1102-0319

Journal of the American Society of Nephrology

Copyright © 2000 by the American Society of Nephrology

Results

Chronic Renal Disease

Eight studies, containing a total of 2229 patients, were selected for meta-analysis (7–14) (Table 1). The mean age of the patients was 48.1 ± 2.4 with a mean duration of follow-up of 62.2 ± 25.8 mo. Five other studies could not be included in the analysis because they did not report sufficient statistical data to calculate effect size (15–19). Of these excluded studies, two ($n = 836$) concluded that the progression of nondiabetic renal disease was more rapid in men than in women, while three others ($n = 751$) found no significant gender difference in renal disease progression.

Using a fixed-effects model, the overall effect size (d) for the association between male gender and renal disease progression was 0.3619 (95% CI, 0.27 to 0.45) (Figure 1). The positive association was highly significant (mean weighted correlation [r] = 0.1781, $P < 0.00001$). All correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 12.238$, $P = 0.1409$).

Meta-analysis using the fixed-effects model was repeated using four studies (7,10,12,13) that contained 1664 patients, after exclusion of four studies that used an outcome measure other than ESRD requiring renal replacement therapy or a decline in isotopically determined GFR. Excluded studies used a rise in serum creatinine ($n = 3$) or a decline in creatinine clearance ($n = 1$) as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.3036 (95% CI, 0.20 to 0.41). The positive association was highly significant (mean weighted correlation [r] = 0.1501, $P < 0.00001$). All correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 2.418$, $P = 0.6593$).

Calculations were repeated using a random-effects model (5). The overall effect size for the association between male gender and renal disease progression was 0.25601, indicating that male gender was associated with a worse outcome in chronic renal disease. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 1.21852$, $P > 0.05$). Meta-analysis using the random-effects model was repeated using the four studies (7,10,12,13) that utilized ESRD or change in isotopically determined GFR as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.25601. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 0.365992$, $P > 0.05$).

IgA Nephropathy

Twenty-five studies (13,20–42,48), containing a total of 3127 patients, were selected for meta-analysis (Table 1). The mean age of the patients was 26.0 ± 2.1 yr with an average follow-up of 63.6 ± 9.7 mo. Five studies were performed in a pediatric population, while the remaining studies included only adults. Thirteen other studies (44–47,49–56) ($n = 1967$) could not be included in the analysis because they did not report

sufficient statistical data to calculate effect size. Twelve of 13 excluded studies found no significant gender difference in renal disease progression. Using a fixed-effects model, the overall effect size for the association between male gender and renal disease progression was 0.2012 (95% CI, 0.12 to 0.28) (Figure 2). The positive association was highly significant (mean weighted correlation [r] = 0.1001, $P < 0.00001$). Twenty-one of the 25 correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was significant, indicating heterogeneity of effect size ($Q = 64.468$, $P < 0.00001$).

Meta-analysis was repeated using 16 studies (13,21,22,24,26,27,32–40,42) that contained 1464 patients, after exclusion of nine studies that used an outcome measure other than ESRD or a decline in isotopically determined GFR. Excluded studies used a rise in serum creatinine ($n = 5$), a decline in creatinine clearance ($n = 1$), or the development of “chronic renal failure” ($n = 3$) as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.1428 (95% CI, 0.03 to 0.25). The positive association was significant (mean weighted correlation [r] = 0.0712, $P = 0.0043$). Thirteen of the 16 correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was significant, indicating heterogeneity of effect size ($Q = 51.042$, $P < 0.00001$).

Calculations were repeated using a random-effects model (5). The overall effect size for the association between male gender and renal disease progression was 0.234743, indicating that male gender was associated with a worse outcome in IgA nephropathy. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 2.443954$, $P > 0.05$). Meta-analysis using the random-effects model was repeated using the 16 studies (13,21,22,24,26,27,32–40,42) that used ESRD or change in isotopically determined GFR as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.201413. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 2.076299$, $P > 0.05$).

Membranous Nephropathy

Twenty-one studies (13,43,57–75), containing a total of 1894 patients, were selected for meta-analysis (Table 1). The mean age of the patients was 43.9 ± 1.3 yr with an average follow-up of 83.7 ± 11.9 mo. Five other studies (76–80) ($n = 651$) could not be included in the analysis because they did not report sufficient statistical data to calculate effect size. All five excluded studies found no significant gender difference in renal disease progression. Using a fixed-effects model, the overall effect size for the association between male gender and renal disease progression was 0.2309 (95% CI, 0.14 to 0.32) (Figure 3). The positive association was highly significant (mean weighted correlation [r] = 0.1147, $P < 0.00001$). In 17 of 23 studies, correlation coefficients were positive in the direction of an unfavorable renal outcome in male patients. The Q statistic was significant, indicating heterogeneity of effect size ($Q =$

Table 1. Studies analyzed by meta-analysis^a

| | Year of Publication | Mean Age (yr) | <i>n</i> | Men | Women |
|-----------------------|---------------------|---------------|----------|-----|-------|
| Chronic renal disease | | | | | |
| Coggins (7) | 1998 | 52 | 585 | 357 | 228 |
| Coggins (7) | 1998 | 52 | 255 | 151 | 104 |
| Hannedouche (8) | 1993 | 51 | 223 | 126 | 97 |
| Hunt (10) | 1998 | 37 | 246 | 156 | 90 |
| Jungers (9) | 1995 | 46 | 159 | 108 | 51 |
| Rosman (11) | 1989 | | 113 | 62 | 51 |
| Ruggenenti (12) | 1998 | 52 | 98 | 79 | 19 |
| Simon (13) | 1994 | | 480 | 99 | 381 |
| Williams (14) | 1998 | | 70 | 47 | 23 |
| IgA nephropathy | | | | | |
| Alamartine (20) | 1991 | 28 | 282 | 222 | 60 |
| Berg (38) | 1993 | 9 | 36 | 22 | 14 |
| Bogenshutz (21) | 1990 | 33 | 239 | 176 | 63 |
| Boyce (33) | 1986 | 35 | 112 | 90 | 22 |
| Chida (22) | 1985 | 28 | 81 | 43 | 38 |
| D'Amico (48) | 1985 | 30 | 92 | 57 | 35 |
| Droz (23) | 1984 | | 244 | 173 | 71 |
| Frimat (24) | 1997 | 36 | 210 | 173 | 37 |
| Hogg (42) | 1994 | 11 | 80 | 57 | 23 |
| Hood (27) | 1981 | 26 | 37 | 27 | 10 |
| Kobayashi (36) | 1988 | 30 | 29 | 15 | 14 |
| Kobayashi (37) | 1989 | 34 | 42 | 21 | 21 |
| Levy (40) | 1985 | 9 | 91 | 63 | 28 |
| Nicholls (28) | 1983 | 32 | 212 | 155 | 57 |
| Packham (25) | 1996 | | 204 | 106 | 98 |
| Propper (29) | 1987 | 29 | 61 | 51 | 10 |
| Rambausek (35) | 1987 | 33 | 131 | 90 | 41 |
| Rekola (26) | 1991 | 38 | 77 | 60 | 17 |
| Simon (13) | 1994 | | 161 | 72 | 89 |
| Van der Peet (32) | 1977 | 28 | 25 | 21 | 4 |
| Velo (30) | 1987 | 22 | 97 | 61 | 36 |
| Woo (34) | 1987 | 26 | 151 | 110 | 41 |
| Wyatt (31) | 1993 | 36 | 128 | 90 | 38 |
| Wyatt (39) | 1995 | 11 | 103 | 70 | 33 |
| Yoshikawa (41) | 1992 | 10 | 200 | 122 | 78 |
| ADPKD | | | | | |
| Bear (81) | 1992 | | 42 | | |
| Choukroun (82) | 1995 | 46 | 109 | 57 | 52 |
| Choukroun (82) | 1995 | 49 | 48 | 27 | 21 |
| Conte (91) | 1995 | | 325 | 136 | 189 |
| Conte (91) | 1995 | | 642 | 321 | 321 |
| Geberth (88) | 1995 | | 74 | 40 | 34 |
| Geberth (88) | 1995 | | 74 | 44 | 30 |
| Gonzalo (89) | 1996 | | 82 | 52 | 30 |
| Gonzalo (90) | 1996 | 32 | 30 | 6 | 24 |
| Higashihara (86) | 1992 | | 72 | 42 | 30 |
| Johnson (83) | 1997 | | 388 | | |
| MDRD (84) | 1995 | | 141 | 79 | 62 |
| MDRD (84) | 1995 | | 59 | 34 | 25 |
| Simon (92) | 1995 | | 63 | 30 | 33 |
| Stewart (85) | 1994 | | 1157 | 630 | 527 |
| Torra (87) | 1996 | | 38 | | |

Table 1.—Continued

| | Year of Publication | Mean Age (yr) | <i>n</i> | Men | Women |
|------------------------|---------------------|---------------|----------|-----|-------|
| Membranous nephropathy | | | | | |
| Abe (57) | 1986 | 39 | 89 | 45 | 44 |
| Bone (74) | 1996 | 50 | 42 | 25 | 17 |
| Cameron (58) | 1990 | 45 | 103 | 87 | 16 |
| Collaborative (59) | 1979 | | 72 | 42 | 30 |
| Davison (60) | 1984 | | 62 | 45 | 17 |
| Donadio (73) | 1988 | 50 | 140 | 93 | 47 |
| Durin (72) | 1990 | | 82 | 48 | 34 |
| Fuiano (61) | 1989 | 49 | 25 | 14 | 11 |
| Honkanen (62) | 1994 | 41 | 72 | 53 | 19 |
| Hopper (63) | 1981 | 43 | 100 | 65 | 35 |
| Hunt (75) | 1992 | 40 | 83 | 60 | 23 |
| Jindal (64) | 1992 | 50 | 26 | 22 | 4 |
| MacTier (65) | 1986 | 43 | 26 | 22 | 4 |
| Murphy (43) | 1988 | 36 | 139 | 77 | 62 |
| Ponticelli (66) | 1984 | 44 | 62 | 49 | 13 |
| Ramzy (67) | 1981 | 35 | 35 | 18 | 17 |
| Schieppati (68) | 1993 | 51 | 100 | 68 | 32 |
| Simon (13) | 1994 | | 85 | 43 | 42 |
| Toth (69) | 1994 | 43 | 100 | 52 | 48 |
| Tu (70) | 1984 | 44 | 117 | 75 | 42 |
| Wehrmann (71) | 1989 | | 334 | 223 | 111 |

^a ADPKD, autosomal dominant polycystic kidney disease.

35.624, $P = 0.0333$). Meta-analysis was repeated using a fixed-effects model with 12 studies (13,43,63–65,67,68,70–73,75) that contained 1267 patients, after exclusion of nine studies that used an outcome measure other than ESRD or a decline in isotopically determined GFR. Excluded studies used a rise in serum creatinine ($n = 5$) or the development of “chronic renal failure” ($n = 4$) as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.3188 (95% CI, 0.20 to 0.44). The positive association was highly significant (mean weighted correlation [r] = 0.1574, $P < 0.00001$). In 10 of the 12 studies, correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 12.908$, $P = 0.2994$).

Calculations were repeated using a random-effects model (5). The overall effect size for the association between male gender and renal disease progression was 0.21635, indicating that male gender was associated with a worse outcome in membranous nephropathy. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 3.015111$, $P > 0.05$). Meta-analysis using the random-effects model was repeated using the 12 studies (13,43,63–65,67,68,70–73,75) that utilized ESRD or change in isotopically determined GFR as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.330358. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 1.44415$, $P > 0.05$).

ADPKD

Twelve studies (81–92), containing a total of 3344 patients, were selected for meta-analysis (Table 1). Four other studies (93–96) ($n = 349$) were not included in the analysis because they did not report sufficient statistical data to calculate effect size. All four excluded studies found no significant gender difference in renal disease progression. Using a fixed-effects model, the overall effect size for the association between male gender and renal disease progression was -0.1516 (95% CI, -0.22 to -0.08) (Figure 4). The negative association achieved statistical significance (mean weighted correlation [r] = -0.0756 , $P < 0.00001$). The Q statistic was significant, indicating heterogeneity of effect size ($Q = 830.932$, $P < 0.00001$). Despite the fact that 10 of the 12 studies showed a positive correlation coefficient in the direction of an unfavorable renal outcome in males, one egregious outlier (91) ($n = 967$) led to an overall negative effect size. Removal of this outlier resulted in a significant positive overall effect size ($d = 0.2818$, 95% CI, 0.20 to 0.36, $r = 0.1395$, $P < 0.00001$, $Q = 27.955$, $P = 0.0092$), indicating that male gender was associated with more rapid progression of ADPKD.

Meta-analysis was repeated with a fixed-effects model using eight studies (81,83–89) that contained 2127 patients, after exclusion of four studies that used an outcome measure other than age of onset of renal replacement therapy or a decline in isotopically determined GFR. Excluded studies used a rise in serum creatinine ($n = 3$) or a decline in creatinine clearance ($n = 1$) as an outcome measure. The overall effect size for the




Figure 1. Effect size and 95% confidence interval (CI) for individual studies of the effect of gender on the progression of chronic renal disease of mixed etiology. The overall mean effect size and 95% CI is shown on top. A positive value indicates that male gender is associated with an adverse renal outcome.

association between male gender and renal disease progression was 0.2469 (95% CI, 0.16 to 0.33). The positive association was significant (mean weighted correlation [r] = 0.1225, $P < 0.00001$). In seven of the eight studies, correlation coefficients were positive in the direction of an unfavorable renal outcome in males. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 13.422$, $P = 0.1444$).

Results obtained using a random-effects model (5) differed from those obtained with the fixed-effects model. The overall effect size for the association between male gender and renal disease progression was 0.07955, indicating that male gender was associated with a worse outcome in ADPKD. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 14.6004$, $P > 0.05$). Meta-analysis using the random-effects model was repeated using the eight studies (81,83–89) that utilized age of onset of renal replacement therapy or a decline in isotopically determined GFR as an outcome measure. The overall effect size for the association between male gender and renal disease progression was 0.351261. The Q statistic was not significant, indicating homogeneity of effect size ($Q = 1.363283$, $P > 0.05$).




Figure 2. Effect size and 95% CI for individual studies of the effect of gender on the progression of IgA nephropathy. The overall mean effect size and 95% CI is shown on top. A positive value indicates that male gender is associated with an adverse renal outcome.

Meta-Regression Analysis

We performed a meta-regression analysis to delineate possible reasons for heterogeneity among the studies. The analysis revealed no significant relationship between standardized effect size and the following variables: year of publication, total number of subjects, number of male subjects, number of female subjects, mean patient age, year of study publication, immunosuppressive therapy, minimum duration of follow-up, mean duration of follow-up, outcome measure, study quality, or type of renal disease.

A funnel plot was constructed of standardized effect size versus subject number (Figure 5). The equal distribution of points above and below the mean standardized effect size for small n values suggests the absence of “file-drawer publication bias” (6).

Discussion

Although we have hypothesized that gender influences the progression of nondiabetic chronic renal disease, this is not a view shared by all investigators (1,2). Individual published reports have yielded conflicting results (1). This is not surprising since variability may arise due to small numbers of subjects




Figure 3. Effect size and 95% CI for individual studies of the effect of gender on the progression of membranous nephropathy. The overall mean effect size and 95% CI is shown on top. A positive value indicates that male gender is associated with an adverse renal outcome.

or short patient follow-up. Also, different treatment regimens may obscure any effects of gender on renal disease outcome. The debate is intensified by the paucity of prospective studies with large sample size and extended patient follow-up. Under these circumstances, any nonanalytical overview of the published literature is subject to bias. In light of these issues, we conducted a meta-analysis to determine the effect of gender on the progression of nondiabetic chronic renal disease.

Our meta-analysis clearly indicates that gender is an important factor influencing the progression of nondiabetic chronic renal disease. However, meta-analysis is itself subject to numerous inherent limitations. The first of these is publication bias. Few studies have been performed specifically to evaluate the role of gender on renal disease progression. Studies in which the investigators did not find gender to be a significant covariate may not report gender-specific statistical data. These negative unreported or under-reported results are obviously lost to the meta-analysis. However, a funnel plot of our data failed to reveal any such “file drawer bias.”

In addition, we carefully analyzed all studies that were excluded from our meta-analysis because they failed to report




Figure 4. Effect size and 95% CI for individual studies of the effect of gender on the progression of autosomal dominant polycystic kidney disease. The overall mean effect size and 95% CI is shown on top. A negative value indicates that female gender is associated with an adverse renal outcome.

sufficient statistical data. Most of the excluded studies concluded that gender had no significant effect on renal disease progression. Although this result appears to detract from the validity of the meta-analysis, it is important to note that a study may fail to find a significant difference between men and women but still yield a positive effect size in favor of an adverse renal outcome in men and thus contribute to an overall positive effect size. In fact, this occurred with many of the studies included in our meta-analysis.

Studies that assess the rate of decline in renal functions by measuring serum creatinine levels or time until dialysis in men *versus* women must be interpreted cautiously. Men ingest more protein and have a larger muscle mass than women, which accounts for an increased rate of creatinine generation. This may contribute to apparent gender-related differences in renal disease progression in studies relying only on serum creatinine measurements to assess renal function. To address this issue, we repeated our meta-analyses after excluding all studies that used serum creatinine as an end point. When we restricted our analysis to studies that used ESRD requiring renal replacement therapy or a decline in true GFR as an outcome measure, male




Figure 5. Funnel plot of standardized effect size versus subject number. The horizontal line shows the mean standardized effect size. One outlier study (91) falls off the plot ($n = 642$, $d = -3.32$).

gender again adversely influenced the outcome of chronic renal disease.

The quality of a meta-analysis is no better than that of its component studies. Many of the studies we analyzed were retrospective with limited sample size and limited duration of patient follow-up. Others used less than ideal outcome measures or failed to adequately report or analyze censored subjects. However, the overall validity of our conclusion is supported by the highly significant association obtained between male gender and adverse renal outcome in our analysis of CRD, IgA nephropathy, and membranous nephropathy. This was true using both the fixed-effects and random-effects models. In addition, the individual correlation coefficients in the large majority of studies were positive, suggesting that the overall positive effect size was not due to chance alone. Moreover, the effect sizes were homogeneous in the CRD analysis. In the membranous nephropathy and IgA nephropathy meta-analyses, homogeneity of effect size was present when a random-effects model was used and could be achieved with the fixed-effects model by merely eliminating one or two outlier studies (data not shown).

A detailed discussion of our ADPKD data is warranted. Despite the fact that 11 of the 13 studies showed a positive correlation coefficient in the direction of an unfavorable renal outcome in men, one egregious outlier (91) led to the opposite result using a fixed-effects model. Removal of the flagrant outlier resulted in a significant *positive* overall effect size, indicating that male gender was associated with more rapid progression. However, a random-effects model may be a more appropriate model to use, given the marked heterogeneity among the studies. In fact, the random-effects model of DerSimonian and Laird (5) yielded a positive overall effect size, indicating that male gender was associated with a worse outcome in ADPKD.

The outlier study was performed by the Italian ADPKD Cooperative Study Group and was reported in a non-peer-

reviewed publication (91). This prospective study performed serial measurements of serum creatinine over 54 mo in 325 hypertensive and 642 normotensive subjects with ADPKD and a baseline serum creatinine value <1.4 mg/dl. These investigators found a more rapid rate of progression in women compared with men, especially among normotensive subjects. In contrast, the Modification of Diet in Renal Disease Study, a prospective multicenter study that included 141 subjects with ADPKD and moderate impairment of function, found a significantly greater decline in renal function, measured by iothalamate clearance, in men with ADPKD compared with women (84). In addition, five studies have used multivariate analysis to assess the effect of gender on the rate of progression of ADPKD (82–84,91,97). All but the outlier study concluded that male gender was an independent factor contributing to more rapid progression of ADPKD. The reason for these conflicting results is unclear. Although several studies suggest that sexual dimorphism in renal disease progression is seen only in the early stages of ADPKD and is lost in patients with advanced renal impairment (84,92,98), this observation cannot explain the divergent results since the outlier study did not include subjects with severe renal impairment. Perhaps the use of serum creatinine as an outcome measure contributed to the anomalous result in the outlier study.

Our meta-analysis clearly indicates that gender is an important factor influencing the progression of some nondiabetic chronic renal diseases. However, we were unable to determine whether the presence of testosterone or the absence of estrogen is a determining factor. Moreover, we were unable to assess whether any renoprotective effects of female gender are limited to premenopausal women, as would be expected if estrogen is critical. In this regard, two prospective studies suggest that the renal protection afforded by female gender is only evident in premenopausal women (7,13). Moreover, our analysis cannot assess whether the effects of gender on renal disease progression are independent of other covariates such as diet, BP, or

serum lipid levels. Our laboratory has performed *in vitro* studies that indicate that sex hormones have effects on mesangial cell biology that may directly influence the course of chronic renal disease (1,99–106). Other investigators have shown that manipulation of the hormonal environment influences the progression of experimental models of chronic renal disease (1). Although the effects of sex hormones on dietary intake, BP, and serum lipid levels were not measured in most of these studies, sex hormones can influence the progression of experimental renal disease independent of these factors (1).

An independent role for gender in the progression of renal disease in humans has not been clearly established (1). Few studies used multivariate analysis to evaluate the role of gender in renal disease progression. Moreover, the results of these multivariate analyses have been conflicting. Six studies used multivariate analysis to analyze the effect of gender on the rate of progression of chronic renal disease of mixed etiologies (7–10,16,107). Three of these studies showed male gender to be an independent determinant of adverse renal outcome, whereas three others did not. By univariate analysis, the Modification of Diet in Renal Disease Study identified male gender as a risk factor for more rapid decline in renal function in 840 primarily nondiabetic subjects with chronic renal disease (7). However, multivariate analysis showed that only proteinuria, HDL levels, and BP independently contributed to a worse renal outcome (7).

Eleven studies used multivariate analysis to analyze the effect of gender on the rate of progression of IgA nephropathy (20,24,42,45,48–53,56). Only two of these studies found male gender to be an independent determinant of an adverse renal outcome, while nine others did not. Eleven studies used multivariate analysis to analyze the effect of gender on the rate of progression of membranous nephropathy (62,69–71,73,75–79). Four of these studies found male gender to be an independent determinant of an adverse renal outcome, while seven others did not. Consistent with our finding that male gender is associated with a less favorable course in patients with membranous nephropathy, two groups of investigators performed pooled patient analyses that yielded an identical conclusion (108,109). Hogan *et al.* (108) reviewed 32 studies that evaluated the outcome of membranous nephropathy and found that male gender was a significant predictor of reaching a renal end point. Reichert *et al.* (109) performed a pooled patient analysis of 810 male and 438 female subjects with membranous nephropathy included in 12 published studies and found that the odds ratio for deterioration of renal function in males was 3.5 (95% CI, 2.5 to 4.9). Similarly, Laluck and Cattran (110) found that lower levels of proteinuria and female gender were the only independent factors associated with remission of proteinuria in patients with membranous nephropathy.

In conclusion, our analysis of the published literature indicates that male gender is associated with a more rapid rate of progression and a worse renal outcome in patients with chronic renal disease.

References

1. Silbiger S, Neugarten J: The impact of gender on the progression of chronic renal disease. *Am J Kidney Dis* 25: 515–533, 1995
2. D'Amico G: Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy and membranoproliferative glomerulonephritis: Survey of the recent literature. *Am J Kidney Dis* 20: 315–323, 1992
3. Hedges LV, Olkin I: *Statistical Methods for Meta-Analysis*, Orlando, FL, Academic Press, 1985
4. Johnson BT: *DSTAT 1.10: Software for the Meta-Analytic Review of Research Literatures*, Hillsdale, NJ, Lawrence Erlbaum Associates, 1993
5. DerSimonian R, Laird N: Meta-analysis in clinical trials. *Control Clin Trials* 7: 177–188, 1986
6. Kasiske BL: Meta-analysis as a clinical tool in nephrology. *Kidney Int* 53: 819–825, 1998
7. Coggins CH, Lewis JB, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. *Nephrol Dial Transplant* 13: 1430–1437, 1998
8. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B: Factors affecting progression in advanced chronic renal failure. *Clin Nephrol* 39: 312–320, 1993
9. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK: Progression rate to end-stage renal failure in non-diabetic kidney diseases: A multivariate analysis of determinant factors. *Nephrol Dial Transplant* 10: 1353–1360, 1995
10. Hunt LP, Short CD, Mallick NP: Prognostic indicators in patients presenting with the nephrotic syndrome. *Kidney Int* 34: 382–388, 1988
11. Rosman JB, Langer K, Brandl M, Piers-Becht TPM, Van Der Hem GK, ter Wee PM, Donker AJM: Protein-restricted diets in chronic renal failure: A four-year follow-up shows limited indications. *Kidney Int* 36[Suppl 27]: S96–S102, 1989
12. Ruggenti P, Gaspari F, Perna A, Remuzzi G: Cross-sectional longitudinal study of spot morning urine protein:creatinine ratio, 24-hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. *Br Med J* 316: 504–509, 1998
13. Simon P, Ramee MP, Autuly V, Laruelle E, Charasse C, Cam G, Ang KS: Epidemiology of primary glomerular diseases in a French region: Variations according to period and age. *Kidney Int* 46: 1192–1198, 1994
14. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. *Q J Med* 67: 343–354, 1988
15. Hannedouche T, Albouze G, Chauveau P, Lacour B, Jungers P: Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. *Am J Kidney Dis* 21: 131–137, 1993
16. Gerstoft J, Balslov JT, Brahm M, Brun C, Jorgensen F, Jorgensen HE, Larsen M, Larsen S, Lorenzen I, Lober M, Thomsen AC: Prognosis in glomerulonephritis. *Acta Med Scand* 219: 179–187, 1986
17. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Bucciati G, Redaelli B, Giangrande A: Proteinuria and blood pressure as causal components of progression to end-stage renal failure. *Nephrol Dial Transplant* 11: 461–467, 1996
18. Mallick NP, Short CD, Hunt LP: How far since Ellis? The Manchester Study of Glomerular Disease. *Nephron* 46: 113–124, 1987
19. Hannedouche T, Chauveau P, Fehrat A, Albouze G, Jungers P:

- Effect of moderate protein restriction on the rate of progression of chronic renal disease. *Kidney Int* 36[Suppl 27]: S91–S95, 1989
20. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F: Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. *Am J Kidney Dis* 18: 12–19, 1991
 21. Bogenschutz O, Bohle A, Batz C, Wehrmann M, Pressler H, Kendziorra H, Gartner HV: IgA nephritis: On the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. *Am J Nephrol* 10: 137–147, 1990
 22. Chida Y, Tomura S, Takeuchi J: Renal survival rate of IgA nephropathy. *Nephron* 40: 189–194, 1985
 23. Droz D, Kramar A, Nawar T, Noel LH: Primary IgA nephropathy: Prognostic factors. *Contrib Nephrol* 40: 202–207, 1984
 24. Frimat L, Briancon S, Heston D, Aymard B, Renoult E, Huu TC, Kessler M, for L'Association des Nephrologues de l'Est: IgA nephropathy: Prognostic classification of end-stage renal failure. *Nephrol Dial Transplant* 12: 2569–2575, 1997
 25. Packham DK, Yan HD, Hewitson TD, Nicholls KM, Fairley KF, Kincaid-Smith P, Becker GJ: The significance of focal and segmental hyalinosis and sclerosis (FSHS) and nephrotic range proteinuria in IgA nephropathy. *Clin Nephrol* 46: 225–229, 1996
 26. Rekola S, Bergstrand A, Bucht H: Deterioration of GFR in IgA nephropathy as measured by ⁵¹Cr-EDTA clearance. *Kidney Int* 40: 1050–1054, 1991
 27. Hood SA, Velosa JA, Holley KE, Donadio JV: IgA-IgG nephropathy: Predictive indices of progressive disease. *Clin Nephrol* 16: 55–62, 1981
 28. Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P: The clinical course of mesangial IgA associated nephropathy in adults. *Q J Med* 53: 227–250, 1984
 29. Propper DJ, Power DA, Simpson JG, Edward N, Catto GRD: The incidence, mode of presentation, and prognosis of IgA nephropathy in Northeast Scotland. *Semin Nephrol* 7: 363–366, 1987
 30. Velo M, Lozano L, Egido J, Gutierrez-Millet V, Hernando L: Natural history of IgA nephropathy in patients followed up for more than ten years in Spain. *Semin Nephrol* 7: 346–350, 1987
 31. Wyatt RJ, Woodford SY, Julian BA: Association of macroscopic hematuria and gender with prognosis in IgA nephropathy [Abstract]. *J Am Soc Nephrol* 4: 691, 1993
 32. van der Peet J, Arisz L, Brentjens JRH, Marrink J, Hoedemaeker PHJ: The clinical course of IgA nephropathy in adults. *Clin Nephrol* 8: 335–340, 1977
 33. Boyce NW, Holdsworth SR, Thomson NM, Atkins RC: Clinicopathological associations in mesangial IgA nephropathy. *Am J Nephrol* 6: 246–252, 1986
 34. Woo KT, Chiang GSC, Lau YK, Lim CH: IgA nephritis in Singapore: Clinical, prognostic indices, and treatment. *Semin Nephrol* 7: 379–381, 1987
 35. Rambašek M, Rauterberg EW, Waldherr R, Demaine A, Krupp G, Ritz E: Evolution of IgA glomerulonephritis: Relation to morphology, immunogenetics, and bp. *Semin Nephrol* 7: 370–373, 1987
 36. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M: Steroid therapy in IgA nephropathy: A retrospective study in heavy proteinuric cases. *Nephron* 48: 12–17, 1988
 37. Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Tateno S: Moderately proteinuric IgA nephropathy: Prognostic prediction of individual clinical courses and steroid therapy in progressive cases. *Nephron* 53: 250–256, 1989
 38. Berg UB, Widstam-Attorps UC: Follow-up of renal function and urinary protein excretion in childhood IgA nephropathy. *Pediatr Nephrol* 7: 123–129, 1993
 39. Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy S, Holland NH, Jackson E, Bishop NA: IgA nephropathy: Long-term prognosis for pediatric patients. *J Pediatr* 127: 913–919, 1995
 40. Levy M, Gonzalez-Burchard G, Broyer M, Dommergues J, Foulard M, Sorez J, Habib R: Berger's disease: Natural history and outcome. *Medicine* 64: 157–180, 1985
 41. Yoshikawa N, Ito H, Nakamura H: Prognostic indicators in childhood IgA nephropathy. *Nephron* 60: 60–67, 1992
 42. Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA: Prognostic indicators in children with IgA nephropathy: Report of the Southwest Pediatric Nephrology Study Group. *Pediatr Nephrol* 8: 15–20, 1994
 43. Murphy BF, Fairley KF, Kincaid-Smith PS: Idiopathic membranous glomerulonephritis: Long-term follow-up in 139 cases. *Clin Nephrol* 30: 175–181, 1988
 44. Syre G: IgA mesangial glomerulonephritis: Significance and pathogenesis of segmental-focal glomerular lesions. *Virchows Arch A Pathol Anat Histopathol* 402: 11–24, 1983
 45. Nieuwhof C, Kruytzer M, Frederiks P, van Breda Vriesman PJC: Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. *Am J Kidney Dis* 31: 962–970, 1998
 46. Hoy WE, Hughson MD, Smith SM, Megill DM: Mesangial proliferative glomerulonephritis in southwestern American Indians. *Am J Kidney Dis* 21: 486–496, 1993
 47. Magil AB, Ballon HS: IgA nephropathy: Evolution of prognostic factors in patients with moderate disease. *Nephron* 47: 246–252, 1987
 48. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Di Belgioioso GB, Imbasciati E, Ragni A, Bertoli S, Fogazzi G, Duca G: Prognostic indicators in idiopathic IgA mesangial nephropathy. *Q J Med* 59: 363–378, 1986
 49. Cattran DC, Greenwood C, Ritchie S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. *Am J Kidney Dis* 23: 247–254, 1994
 50. Koyama A, Igarashi M, Kobayashi M, and The Research Group on Progressive Renal Diseases: Natural history and risk factors for immunoglobulin A nephropathy in Japan. *Am J Kidney Dis* 29: 526–532, 1997
 51. Ibels LS, Gyory A: IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. *Medicine* 73: 79–102, 1994
 52. Johnston PA, Brown JS, Braumholts DA, Davison AM: Clinicopathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: A report from the MRC glomerulonephritis registry. *Q J Med* 84: 619–627, 1992
 53. Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K, Omura T, Fujimi S: An important role of glomerular segmental lesions on progression of IgA nephropathy: A multivariate analysis. *Clin Nephrol* 41: 191–198, 1994
 54. Lee HS, Koh HI, Lee HB, Park HC: IgA nephropathy in Korea: A morphological and clinical study. *Clin Nephrol* 27: 131–140, 1987
 55. Mustonen J, Pasternack A, Helin H, Nikkila M: Clinicopatho-

- logic correlations in a series of 143 patients with IgA glomerulonephritis. *Am J Nephrol* 5: 150–157, 1985
56. Radford MG, Donadio JV, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. *J Am Soc Nephrol* 8: 199–207, 1996
 57. Abe S, Amagasaki Y, Konishi K, Kato E, Iyori S, Sakaguchi H: Idiopathic membranous glomerulonephritis: Aspects of geographical differences. *J Clin Pathol* 39: 1193–1198, 1986
 58. Cameron JS, Healy MJR, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. *Q J Med* 74: 133–156, 1990
 59. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. *N Engl J Med* 301: 1301–1306, 1979
 60. Davison AM, Cameron JS, Kerr DNS, Ogg CS, Wilkinson RW: The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. *Clin Nephrol* 22: 61–67, 1984
 61. Fuiano G, Stanziale P, Balletta M, Sepe V, Marinelli G, Comi N, Esposito A, Andreucci VE: Effectiveness of steroid therapy in different stages of membranous nephropathy. *Nephrol Dial Transplant* 4: 1022–1029, 1989
 62. Honkanen E, Tornroth T, Gronhagen-Riska C, Sankila R: Long-term survival in idiopathic membranous glomerulonephritis: Can the course be clinically predicted? *Clin Nephrol* 41: 127–134, 1994
 63. Hopper J Jr, Trew PA, Biava CG: Membranous nephropathy: Its relative benignity in women. *Nephron* 29: 18–24, 1981
 64. Jindal K, West M, Bear R, Goldstein M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. *Am J Kidney Dis* 19: 61–67, 1992
 65. MacTier R, Boulton Jones JM, Payton CD, McLay A: The natural history of membranous nephropathy in the west of Scotland. *Q J Med* 60: 793–802, 1986
 66. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. *N Engl J Med* 310: 946–950, 1984
 67. Ramzy MH, Cameron JS, Turner DR, Neild GH, Ogg CS, Hicks J: The long-term outcome of idiopathic membranous nephropathy. *Clin Nephrol* 16: 13–19, 1981
 68. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. *N Engl J Med* 329: 85–89, 1993
 69. Toth T, Takebayashi S: Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis. *Int Urol Nephrol* 26: 93–106, 1994
 70. Tu WH, Petitti DB, Biava CG, Tulunay O, Hopper J Jr: Membranous nephropathy: Predictors of terminal renal failure. *Nephron* 36: 118–124, 1984
 71. Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner HV: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. *Clin Nephrol* 31: 67–76, 1989
 72. Durin S, Barbanel C, Landais P, Noel LH, Grunfeld JP: Evolution a long terme des glomerulonephrites extra-membraneuses idiopathiques: Etude des facteurs predictifs de l'insuffisance renale terminale chez 82 malades non traites. *Nephrologie* 11: 67–71, 1990
 73. Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. *Kidney Int* 33: 708–715, 1988
 74. Bone JM, Rustom R, Williams PS: “Progressive” versus “indolent” idiopathic membranous glomerulonephritis. *Q J Med* 90: 699–706, 1997
 75. Hunt LP: Statistical aspects of survival in membranous nephropathy. *Nephrol Dial Transplant Suppl* 1: 53–59, 1992
 76. Cattran DC, Pei Y, Greenwood CMT, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. *Kidney Int* 51: 901–907, 1997
 77. Kibriya MG, Tishkov I, Nikolov D: Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy. *Nephrol Dial Transplant* 9: 138–143, 1994
 78. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. *Kidney Int* 42: 960–966, 1992
 79. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. *N Engl J Med* 320: 8–13, 1989
 80. Zucchelli P, Ponticelli C, Cagnoli L, Passerini P: Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. *Nephrol Dial Transplant* 2: 73–78, 1987
 81. Bear JC, Parfrey PS, Morgan JM, Martin CJ, Cramer BC: Autosomal polycystic kidney disease: New information for genetic counseling. *Am J Med Genet* 43: 548–553, 1992
 82. Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grunfeld JP, Jungers P: Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6: 1634–1642, 1995
 83. Johnson AM, Gabow PA: Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. *J Am Soc Nephrol* 8: 1560–1567, 1997
 84. Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. *J Am Soc Nephrol* 5: 2037–2047, 1995
 85. Stewart JH: End-stage renal failure appears earlier in men than in women with polycystic kidney disease. *Am J Kidney Dis* 24: 181–183, 1994
 86. Higashihara E, Yoshio A, Shimazaki J, Ito H, Koiso K, Sakai O: Clinical aspects of polycystic kidney disease. *J Urol* 147: 329–332, 1992
 87. Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, Estivill X: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. *J Am Soc Nephrol* 7: 2142–2151, 1996
 88. Geberth S, Ritz E, Zeier M, Stier E: Anticipation of age at renal death in autosomal dominant polycystic kidney disease (AD-PKD)? *Nephrol Dial Transplant* 10: 1603–1606, 1995
 89. Gonzalo A, Gallego A, Tato A, Ortuno J: Age at renal replacement therapy in autosomal dominant polycystic kidney disease [Letter]. *Nephron* 74: 620, 1996
 90. Gonzalo A, Gallego A, Rivera M, Orte L, Ortuno J: Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. *Nephron* 72: 225–230, 1996

91. Conte F, Serbelloni P, Milani S, and the Italian ADPKD Cooperative Study Group: Clinical data of a cooperative Italian study of ADPKD. *Contrib Nephrol* 115: 72–87, 1995
92. Simon P, Working Party on ADPKD: Prognosis of autosomal dominant polycystic kidney disease. *Nephron* 71: 247–248, 1995
93. Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH: Prognosis of adult onset polycystic kidney disease re-evaluated. *Kidney Int* 26: 190–193, 1984
94. Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D: Polycystic kidney disease re-evaluated: A population based study. *Q J Med* 290: 477–485, 1991
95. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M: Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. *J Am Soc Nephrol* 4: 1670–1674, 1993
96. Iglesias CG, Torres VE, Offord KP, Holley KE, Beard M, Kurland LT: Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota, 1935–1980. *Am J Kidney Dis* 2: 630–639, 1983
97. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. *Kidney Int* 41: 1311–1319, 1992
98. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E: Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 14: 178–183, 1989
99. Lei J, Silbiger S, Ziyadeh FN, Neugarten J: Serum-stimulated α_1 type IV collagen gene transcription is mediated by TGF- β and inhibited by estradiol. *Am J Physiol* 274: F252–F258, 1998
100. Kwan G, Neugarten J, Sherman M, Ding Q, Fotadar U, Lei J, Silbiger S: Effects of sex hormones on mesangial cell proliferation and collagen synthesis. *Kidney Int* 50: 1173–1179, 1996
101. Neugarten J, Silbiger S: Effects of sex hormones on mesangial cells. *Am J Kidney Dis* 26: 147–151, 1995
102. Silbiger S, Ghossein C, Neugarten J: Estradiol inhibits mesangial cell-mediated oxidation of low density lipoprotein. *J Lab Clin Med* 4: 385–391, 1995
103. Silbiger S, Lei J, Neugarten J: Estradiol suppresses type I collagen synthesis by mesangial cells via activation of AP-1. *Kidney Int* 55: 1268–1276, 1998
104. Silbiger S, Lei J, Ziyadeh FN, Neugarten J: Estradiol reverses TGF- β 1-stimulated type IV collagen gene transcription in murine mesangial cells. *Am J Physiol* 43: F1113–F1118, 1998
105. Neugarten J, Ding Q, Friedman A, Silbiger S: Sex hormones and renal nitric oxide synthases. *J Am Soc Nephrol* 8: 1240–1246, 1997
106. Neugarten J, Silbiger S: The impact of gender on renal transplantation. *Transplantation* 58: 1145–1152, 1994
107. D'Amico G, Gentile MG, Fellin G, Manna G, Cofano F: Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. *Nephrol Dial Transplant* 9: 1590–1594, 1994
108. Hogan SL, Muller KE, Jennette JC, Falk RJ: A review of the therapeutic studies in idiopathic membranous glomerulopathy. *Am J Kidney Dis* 25: 862–875, 1995
109. Reichert LJM, Koene RAP, Wetzels JFM: Prognostic factors in idiopathic membranous nephropathy. *Am J Kidney Dis* 31: 1–11, 1998
110. Laluck BJ, Cattran DC: Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. *Am J Kidney Dis* 33: 1026–1032, 1999